Insights That Move the GPCR Field Forward

Most pharmacologists are trained to chase targets. But what if the real opportunity lies in the chemical matter we throw at them? That’s exactly what Terry’s Corner delivers this week: a deep dive into molecular creativity, rational design, and the overlooked role of chemistry in innovation. Breakthroughs this week: Orphan receptor GPRC5B in neurogenesis; Septerna’s pill-based weight-loss strategy; Atrogi’s new CEO announcement.

Dear Dr. GPCR Community, If the past few years have been about finding our rhythm, this year has been about refining our systems — and stepping confidently into what’s next. When we started Dr. GPCR, it was with a simple goal: to connect people who shared a passion for GPCR science and discovery. What began as a small, volunteer-driven initiative has grown into a vibrant global network — thousands of scientists, founders, students, and partners who now learn, collaborate, a

Join us at the Discovery on Target meeting in Boston for the GPCR Drug Discovery track! I’m honored to chair a session featuring Terry Kenakin, a leader in functional selectivity. We’ll explore GPCR targets like GLP-1R, CXCR4, and dopamine receptors across oncology, metabolic, CNS, and immunology. As Dr. GPCR, we connect scientists and accelerate innovation — see you in Boston!

Allostery isn’t just an advanced concept—it’s essential to understanding efficacy, ligand bias, and receptor behavior in real-world systems.

Hello GPCR Trailblazers, This week, we’re spotlighting Celtarys Research, our newest partner, featured in a blog and podcast with CSO Dr. Maria Majellaro, highlighting their fluorescent ligand tools for live-cell GPCR assays.   After 40+ years and 250 publications, Dr. Terry Kenakin is launching a new learning space with video courses, AMAs, and practical insights . Get a sneak peek  and sign up for The Kenakin Brief—his free weekly newslette r.   On the industry side, Novo N